Antivascular therapy of oral tongue squamous cell carcinoma with PTK787

Laryngoscope

Volumn 115, Issue 12, 2005, Pages 2249-2255

  Yazici, Yasemin D ^a   Kim, Seungwon ^a   Jasser, Samar A ^a   Wang, Zhuoying ^a   Carter Jr , Kenny B ^a   Bucana, Corazan D ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

CPT 11; PTK787; Tongue cancer; VEGF R

Indexed keywords

CAMPTOTHECIN; IRINOTECAN; PROTEIN TYROSINE KINASE INHIBITOR; VASCULAR TARGETING AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB; DRUG DERIVATIVE; PHTHALAZINE DERIVATIVE; PRODRUG; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DRUG COMBINATION; EXPERIMENTAL NEOPLASM; FOLLOW UP; IN VITRO STUDY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; TONGUE TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ANIMALS; CAMPTOTHECIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PHTHALAZINES; PRODRUGS; PROTEIN KINASE INHIBITORS; PYRIDINES; TONGUE NEOPLASMS; TREATMENT OUTCOME;

EID: 33644796029     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000183861.53765.77     Document Type: Article

References (17)

1. Gorsky M, Epstein JB, Oakley C, et al. Carcinoma of the tongue: a case series analysisof clinical presentation, risk factors, staging, and outcome. OralSurg Oral Med Oral Pathol Oral Radiol Endod 2004;98:546-552.
2. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
3. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-674.
4. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000;55:15-35; discussion 35-16.
5. Baillie R, Harada K, Carlile J, et al. Expression of vascular endothelial growth factor in normal and tumour oral tissues assessed with different antibodies. Histochem J 2001; 33:287-294.
6. Swan EA, Jasser SA, Holsinger FC, et al. Acquisition of anoikis resistance is a critical step in the progression of oral tongue cancer. Oral Oncol 2003;39:648-655.
7. Kim SJ, Uehara H, Yazici S, et al. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 2004;64:4201-4208.
8. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited. Nat Rev Cancer 2003;3:453-458.
9. Schneider E, Hsiang YH, Liu LF. DNA topoisomerases as anticancer drug targets. Adv Pharmacol 1990;21:149-183.
10. Masin JS, Berger SJ, Setrakian S, et al. Topoisomerase I activity in squamous cell carcinoma of the head and neck. Laryngoscope 1995;105:1191-1196.
11. Guo B, Cao S, Toth K, et al. Overexpression of Bax enhances antitumor activity of chemotherapeutic agents in human head and neck squamous cell carcinoma. Clin Cancer Res 2000;6:718-724.
12. Yigitbasi OG, Younes MN, Doan D, et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 2004;64:7977-7984.
13. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401-409.
14. Jain RK. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol 2002;29:3-9.
15. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
16. Yokoi K, Thaker PH, Yazici S, et al. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. Cancer Res 2005;65:3716-3725.
17. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189.